Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

Among patients with deficient mismatch repair, stage 3 colorectal cancer and resistance to chemotherapy, Tecentriq (atezolizumab) plus chemotherapy treatment reduced the risk of recurrence or death by 50% compared with chemotherapy treatment alone, according to data from the phase 3 ATOMIC trial which were shared in a press briefing at the 2025 ASCO Annual Meeting.

The trial sought to determine if adding an immune checkpoint inhibitor to standard care would improve outcomes after surgical resection in this population.

“These data establish this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,” said lead author Dr. Frank A. Sinicrope, coleader, Gastrointestinal Cancer Program, and clinical investigator, Mayo Foundation, both in Rochester, Minnesota, during the press briefing.

ATOMIC enrolled 712 patients across more than 300 sites in the National Clinical Trials Network. Patients were eligible if they had resected stage III colon cancer, deficient mismatch repair determined by immunohistochemistry, no prior chemotherapy or radiation, and an ECOG performances status of 2 or less.

After undergoing surgery, patients were randomly assigned to receive Tecentriq plus the standard mFOLFOX6 chemotherapy regimen of oxaliplatin, leucovorin calcium, and fluorouracil, followed by 6 months of Tecentriq in the treatment arm versus mFOLFOX6 alone in the control arm. The primary end point was disease-free survival and secondary end points were overall survival and side effect profile.

At the data cutoff of February 4, 2025, the median follow-up was 37.2 months. At the second interim analysis at 75% of disease-free survival events, it was determined that the study met the protocol-specified boundary for efficacy and the data were released.

At 3 years, the combination resulted in a disease-free survival rate of 86.4% versus 76.6% for chemotherapy alone. “This is a substantial…benefit achieved,” Sinicrope said. Referring to the disease-free survival curves, Sinicrope added that “the [disease-free survival] curve is plateauing, indicating that we’re not seeing any more recurrences or death with the immunotherapy and chemotherapy combination.”

Subgroup analysis also demonstrated a positive disease-free survival benefit across subpopulations defined by age, sex, race, tumor location, and risk group for patients in the mFOLFOX plus Tecentriq arm. In particular, proximal and distal tumor location, T-stage, and risk group demonstrated disease-free survival that favored the treatment versus the control arm.

“No matter the patient’s age, their sex, their race, their location, T-stage, or N-stage, patients are doing better with the addition of immunotherapy to chemotherapy,” Sinicrope said.

The safety of mFOLFOX6 plus Tecentriq was in line with the known safety profiles of each, with a manageable increase in nonfebrile neutropenia.

“We regard [these findings] as a highly impactful study that will change clinical practice, and it actually represents the first immunotherapy adjuvant study in colon cancer,” Sinicrope concluded.

“The most important thing about this study is that it involves a real-world population that I will see in my clinic,” Joel Saltzman, MD, medical oncologist, Taussig Cancer Center, Cleveland Clinic, in Ohio, said during the commentary section of the press briefing. “We have seen patients in whom we thought immunotherapy would be helpful, but we weren’t sure if we could integrate it into their care,” Saltzman continued.

He further noted that “this was a study that took 5 years to accrue patients at more than 300 sites, and it would not have been feasible without the support of federal funding from the National Cancer Institute and our cooperative group network.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.